Martha Shadan

Martha Shadan was the president and chief executive officer at Miach Orthopaedics from 2019 to 2022. During her tenure, she led the company through the FDA approval process and received the first DeNovo in Sports Medicine. During 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led Rotation Medical through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company's acquisition by Smith & Nephew in December 2017.

Shadan has more than three decades of experience in the life science industry as a business leader in a variety of both large and start-up organizations. Prior to joining Rotation Medical, she was the president of the Trauma Division at Zimmer where she managed the P&L for the global business. Shadan served at Covidien as vice president/general manager of Vascular Therapies and vice president/general manager BioSurgery and Sports Surgery. Other companies that have benefited from Shadan's experience and leadership include Bristol Myers Squibb Co. and Merck Millipore.

Shadan is actively involved with the Advanced Medical Technology Association (AdvaMed). She has been on the Board of Directors since 2017 and is a current member and past chair of the Accel Board of Directors. Shadan is the past chair of the Diversity and Inclusion Committee for AdvaMed and is a founding member of the Leadership Circle for the Women's Executive Network (WEN). Shadan serves on the board of CVRx, LeMaitre, Medartis, S2N and is the chair of the board of Brilliant Strings Therapeutics.  She is also a board advisor for several other companies.

Shadan holds a master of business administration from Northeastern University, master of science in biology from Michigan State University, and bachelor of science in biology from the University of New Hampshire.